Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Increases By 8.6%

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the recipient of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 3,150,000 shares, a growth of 8.6% from the November 15th total of 2,900,000 shares. Based on an average daily volume of 321,400 shares, the days-to-cover ratio is currently 9.8 days. Approximately 6.5% of the company’s stock are short sold.

Astria Therapeutics Stock Down 0.8 %

Shares of ATXS traded down $0.08 during mid-day trading on Tuesday, hitting $9.59. 4,516 shares of the company traded hands, compared to its average volume of 589,777. The company has a market capitalization of $541.20 million, a PE ratio of -4.63 and a beta of 0.67. The business has a 50 day moving average of $10.78 and a 200 day moving average of $10.71. Astria Therapeutics has a 1-year low of $5.84 and a 1-year high of $16.90.

Analysts Set New Price Targets

Several equities analysts have issued reports on ATXS shares. Oppenheimer lifted their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, December 10th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $25.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ATXS. Charles Schwab Investment Management Inc. grew its holdings in shares of Astria Therapeutics by 152.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock valued at $3,460,000 after buying an additional 189,727 shares during the last quarter. FMR LLC grew its stake in Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after purchasing an additional 1,767,714 shares during the last quarter. Vestal Point Capital LP increased its holdings in shares of Astria Therapeutics by 23.1% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after purchasing an additional 750,000 shares during the period. Sofinnova Investments Inc. purchased a new position in shares of Astria Therapeutics in the second quarter worth about $552,000. Finally, ClariVest Asset Management LLC purchased a new position in shares of Astria Therapeutics in the second quarter worth about $731,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.